Use of PD-1 inhibitors in patients with end-stage renal disease: safety and clinical outcomes from real-world data
Sign Up to like & getrecommendations! Published in 2022 at "Acta Oncologica"
DOI: 10.1080/0284186x.2022.2127121
Abstract: Jiasheng Wang , Srilatha Dasari, Dina Elantably, Akram Alkrekshi and Yeseong David Kim Department of Hematology and Oncology, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH, USA; Department of Internal Medicine, MetroHealth Medical… read more here.
Keywords: inhibitors patients; end stage; patients end; stage renal ... See more keywords
Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma
Sign Up to like & getrecommendations! Published in 2018 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2018.02749
Abstract: In the biology of multiple myeloma (MM), immune dysregulation has emerged as a critical component for novel therapeutic strategies. This dysfunction is due to a reduced antigen presentation, a reduced effector cell ability and a… read more here.
Keywords: myeloma; use inhibitors; multiple myeloma; pitfalls use ... See more keywords
Interleukin-6 and Macular Edema: A Review of Outcomes with Inhibition
Sign Up to like & getrecommendations! Published in 2023 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms24054676
Abstract: This paper describes the current literature on the molecular pathophysiology of interleukin-6 (IL-6) in the genesis of macular edema and on the outcomes with IL-6 inhibitors in the treatment of non-infectious macular edema. The role… read more here.
Keywords: non infectious; edema; macular edema; use inhibitors ... See more keywords